Trial Profile
A Phase 1, Open-Label, Randomized, Three-Way Crossover Study Evaluating the Relative Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jul 2016
Price :
$35
*
At a glance
- Drugs Relugolix (Primary)
- Indications Prostate cancer
- Focus Pharmacokinetics
- Sponsors Takeda
- 26 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Mar 2015 New trial record